The project is part of the EuroTransBio Initiative and is coordinated by the Dutch company Crossbeta Biosciences. The objective is the development of novel vaccine technologies based on certain misfoldings in proteins, called crossbeta structures. The project partners will develop a technique for the general use of crossbeta structures in protein-based vaccine strategies.
Geneart receives a quarter of the total public project funding of about E0.8 million. Aside from optimizing the gene sequences using the proprietary Geneart GeneOptimizer technology for the efficient production of the vaccine, Geneart will also use an iterative process to optimize the design of the desired protein antigen. The objective is the production of an antigen that shows the optimal crossbeta structure for the desired immune response.
Ralf Wagner, CEO of the Geneart, said: “This project supports our activities in the area of targeted protein design. In the medium term, we plan to extend our business and leadership role by offering the design of customized proteins as well. This does not only complement our current services but also adds additional value for our customers, for example in the pharmaceutical industry.”